Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes

Affiliations

¹ Department of Haematology, King's College Hospital, London.
² Department of Haematology, University College London Hospitals, London, UK; UCL Cancer Institute, University College London, London.
³ Department of Haematology, Freeman Hospital, Newcastle University, Newcastle.
⁴ Department of Haematology, Manchester Royal Infirmary, Manchester.
⁵ Department of Haematology, University College London Hospitals, London.
⁶ Department of Medical Oncology, The Christie Hospital, Manchester.
⁷ Department of Haematology, University Hospitals Bristol and Weston, Bristol.
⁸ Department of Haematology, Queen Elizabeth Hospital, Birmingham.
⁹ Department of Haematology, Royal Marsden Hospital, London.
¹⁰ Department of Haematology. University Hospital of Wales, Cardiff.
¹¹ Department of Haematology, Queen Elizabeth Hospital, Glasgow.
¹² Department of Haematology, Cambridge University Hospitals, Cambridge.
¹³ Department of Haematology, Leeds Teaching Hospitals, Leeds.
¹⁴ Department of Haematology, King's College Hospital, London, UK; Comprehensive Cancer Centre, King's College London, London.
¹⁵ Department of Haematology, The Christie Hospital, Manchester.
¹⁶ CR UK and UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London.
¹⁷ Department of Haematology, King's College Hospital, London. andrea.kuhnl@nhs.net.

Christianne Bourlon et al. Haematologica. 2024.

. 2024 Aug 1;109(8):2716-2720.

doi: 10.3324/haematol.2024.285010.

¹ Department of Haematology, King's College Hospital, London.
² Department of Haematology, University College London Hospitals, London, UK; UCL Cancer Institute, University College London, London.
³ Department of Haematology, Freeman Hospital, Newcastle University, Newcastle.
⁴ Department of Haematology, Manchester Royal Infirmary, Manchester.
⁵ Department of Haematology, University College London Hospitals, London.
⁶ Department of Medical Oncology, The Christie Hospital, Manchester.
⁷ Department of Haematology, University Hospitals Bristol and Weston, Bristol.
⁸ Department of Haematology, Queen Elizabeth Hospital, Birmingham.
⁹ Department of Haematology, Royal Marsden Hospital, London.
¹⁰ Department of Haematology. University Hospital of Wales, Cardiff.
¹¹ Department of Haematology, Queen Elizabeth Hospital, Glasgow.
¹² Department of Haematology, Cambridge University Hospitals, Cambridge.
¹³ Department of Haematology, Leeds Teaching Hospitals, Leeds.
¹⁴ Department of Haematology, King's College Hospital, London, UK; Comprehensive Cancer Centre, King's College London, London.
¹⁵ Department of Haematology, The Christie Hospital, Manchester.
¹⁶ CR UK and UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London.
¹⁷ Department of Haematology, King's College Hospital, London. andrea.kuhnl@nhs.net.

No abstract available

Figures

1. Locke FL, Ghobadi A, Jacobson CA, et al. . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31-42. - PMC - PubMed
1. Schuster SJ, Tam CS, Borchmann P, et al. . Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403-1415. - PubMed
1. Jacobson CA, Locke FL, Ma L, et al. . Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther. 2022;28(9):581.e1-581.e8. - PMC - PubMed
1. Bachy E, Le Gouill S, Di Blasi R, et al. . A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145-2154. - PMC - PubMed
1. Kwon M, Iacoboni G, Reguera JL, et al. . Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108(1):110-121. - PMC - PubMed